AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7067358 — intervention group
Group type: COMPARATOR
Intervention: Loading restricted to the initial, accelerating phase of inspiratory air flow
Number of subjects: 10
Study 30674601 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP‐1002 (75 million cells)
Number of subjects: 25
Study 30674601 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP‐1002
Number of subjects: 25
Study 30674601 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 25
Study 28624898 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated diabetes care programme (DIAPREM) with quarterly clinical appointments
Number of subjects: 150
Study 28624898 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (Control Group)
Number of subjects: 150
Study 28624898 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated diabetes care programme (DIAPREM)
Number of subjects: 150
Study 25197740 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical cleaning with interdental brushes combined with cetylpyridinium chloride (0.3% CPC) gel
Number of subjects: 40
Study 25197740 — intervention group
Group type: COMPARATOR
Intervention: Mechanical cleaning with interdental brushes alone
Number of subjects: 40
Study 23537123 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD + IMP
Number of subjects: 42
Study 23537123 — intervention group
Group type: COMPARATOR
Intervention: OFD alone
Number of subjects: 42
Study 22511260 — intervention group
Group type: EXPERIMENTAL
Intervention: AGE-LDL-ICs
Number of subjects: 517
Study 22511260 — intervention group
Group type: EXPERIMENTAL
Intervention: oxLDL-ICs
Number of subjects: 517
Study 22511260 — intervention group
Group type: EXPERIMENTAL
Intervention: AGE-LDL-ICs and oxLDL-ICs
Number of subjects: 517
Study 19299272 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) with anti-inflammatory agent (60 mg oral acemetacine twice daily for 10 days)
Number of subjects: 50
Study 19299272 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (Ca-nadroparin 190 IUAxa/kg in a single dose)
Number of subjects: 50
Study 17516022 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg once-yearly for 2, 3 or 5 years
Number of subjects: 119
Study 17516022 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg once-yearly
Number of subjects: 119
Study 17516022 — intervention group
Group type: COMPARATOR
Intervention: Calcium only
Number of subjects: 119
Study 15468607 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (50-100 mg)
Number of subjects: 15
Study 15468607 — intervention group
Group type: COMPARATOR
Intervention: Zaleplon (10-20 mg)
Number of subjects: 15
Study 11790899 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial body weight (PBW) treadmill training
Number of subjects: 10
Study 12886697 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt loaded (300 mmol Na+/day) for 4 days
Number of subjects: 27
Study 12886697 — intervention group
Group type: COMPARATOR
Intervention: Salt restricted (25 mmol Na+/day) for 4 days
Number of subjects: 27
Study 8160096 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy/ten fractions/two weeks (Group A)
Number of subjects: 162
Study 8160096 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Gy/20 fractions/four weeks (Group B)
Number of subjects: 162
Study 8160096 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy/ten fractions/two weeks (Group C)
Number of subjects: 162
Study 8160096 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy/five fractions/one week (Group D)
Number of subjects: 162
Study 3049185 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 30
Study 3049185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30411180 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPREE participants (intervention group)
Number of subjects: 18714
Study 28167747 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Collaborative Care Team (ICCT) services
Number of subjects: 500
Study 28167747 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based treatment as usual
Number of subjects: 500
Study 29911601 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone (OXY)
Number of subjects: 80
Study 29911601 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (IVM) followed by codeine
Number of subjects: 80
Study 23734943 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site integrated psychiatric care
Number of subjects: 316
Study 23734943 — intervention group
Group type: COMPARATOR
Intervention: Off-site non-integrated psychiatric care
Number of subjects: 316
Study 21140258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual Salvinorin A (SA) up to 4 mg
Number of subjects: 8
Study 21140258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 18245546 — intervention group
Group type: EXPERIMENTAL
Intervention: OGX-011 at 640 mg
Number of subjects: 40
Study 18245546 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (30 mg/m2 weekly for 5 of 6 weeks or 75 mg/m2 every 3 weeks)
Number of subjects: 40
Study 16989201 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry air radon baths (DARB) with radon concentration 40 nCi/l
Number of subjects: 0
Study 16989201 — intervention group
Group type: COMPARATOR
Intervention: Dry air radon baths (DARB) with radon concentration 20 nCi/l
Number of subjects: 0
Study 12975739 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium 1.5 mg/kg with neostigmine
Number of subjects: 61
Study 12975739 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium 1.5 mg/kg without neostigmine
Number of subjects: 61
Study 12975739 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium 0.25 mg/kg
Number of subjects: 61
Study 10783183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive clinical case management
Number of subjects: 268
Study 10783183 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based expanded brokerage case management
Number of subjects: 268
Study 8689374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians' housing recommendations
Number of subjects: 86
Study 8689374 — intervention group
Group type: COMPARATOR
Intervention: Consumers' housing preferences
Number of subjects: 86
Study 8689374 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific housing features
Number of subjects: 86
Study 8689374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians' consideration of social background and health status
Number of subjects: 86
Study 1679961 — intervention group
Group type: EXPERIMENTAL
Intervention: Iosimide (low osmolar nonionic contrast media)
Number of subjects: 198
Study 1679961 — intervention group
Group type: COMPARATOR
Intervention: Iopromide (nonionic contrast media)
Number of subjects: 198
Study 1679961 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol (nonionic contrast media)
Number of subjects: 198
Study 1679961 — intervention group
Group type: COMPARATOR
Intervention: Sodium-meglumine-diatrizoate (high osmolar ionic contrast media)
Number of subjects: 198
Study 6594473 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 million units aqueous penicillin G intravenously every four hours for a total of 12 doses (two days) postoperatively
Number of subjects: 40
Study 6594473 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously every four hours for a total of 12 doses (two days) postoperatively
Number of subjects: 40
Study 3083741 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine
Number of subjects: 10
Study 3083741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29471812 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week mild-calorie-restriction (300 kcal/day)
Number of subjects: 80
Study 29471812 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 27879604 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy for 5 days after primary closure
Number of subjects: 100
Study 27879604 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing
Number of subjects: 100
Study 24388729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 38
Study 24388729 — intervention group
Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 38
Study 23147642 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf skeletal muscle index (SMI=D2/Ri)
Number of subjects: 106
Study 23147642 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance muscle indices
Number of subjects: 106
Study 23147642 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf intracellular resistance
Number of subjects: 106
Study 20942667 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and lamivudine plus nevirapine
Number of subjects: 164
Study 20942667 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine and lamivudine plus ritonavir-boosted lopinavir
Number of subjects: 164
Study 19032906 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton yellow laser photocoagulation around the hole margin with oral placebo (vitamin B1)
Number of subjects: 27
Study 19032906 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo (vitamin B1) only
Number of subjects: 27
Study 19032906 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton yellow laser photocoagulation
Number of subjects: 27
Study 15667973 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus hypnotherapy
Number of subjects: 69
Study 15667973 — intervention group
Group type: COMPARATOR
Intervention: Standard curative RT alone
Number of subjects: 69
Study 12523894 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic suppressive oral acyclovir
Number of subjects: 703
Study 12523894 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic suppressive oral acyclovir targeting patients with a history of stromal keratitis
Number of subjects: 703
Study 10656227 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 500 U/day
Number of subjects: 46
Study 10656227 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 46
Study 8660020 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (listening to choice of music before surgery)
Number of subjects: 42
Study 8660020 — intervention group
Group type: COMPARATOR
Intervention: Preoperative instruction alone (control group)
Number of subjects: 42
Study 8660020 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 42
Study 1988724 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-magnesium citrate
Number of subjects: 14
Study 1988724 — intervention group
Group type: COMPARATOR
Intervention: Potassium citrate
Number of subjects: 14
Study 1988724 — intervention group
Group type: COMPARATOR
Intervention: Magnesium citrate
Number of subjects: 14
Study 1988724 — intervention group
Group type: COMPARATOR
Intervention: Potassium chloride
Number of subjects: 14
Study 6340249 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐(beta‐Hydroxyethyl)‐rutoside administered intravenously daily before each radiation
Number of subjects: 31
Study 6340249 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study 30809646 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention (7 group sessions)
Number of subjects: 96
Study 30809646 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 96
Study 29740973 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Unconditional Cash Transfer (6 transfers from April) plus 4 months supplementary feeding
Number of subjects: 0
Study 29740973 — intervention group
Group type: COMPARATOR
Intervention: Standard Unconditional Cash Transfer (4 transfers between June and September) plus 4 months supplementary feeding
Number of subjects: 0
Study 29740973 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Unconditional Cash Transfer plus supplementary feeding
Number of subjects: 0
Study 29740973 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (Modified UCT and Standard UCT)
Number of subjects: 0
Study 27537756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (ventilation group)
Number of subjects: 332
Study 27537756 — intervention group
Group type: COMPARATOR
Intervention: No mechanical ventilation (deflation group)
Number of subjects: 332
Study 25222104 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual (AV) mode
Number of subjects: 23
Study 25222104 — intervention group
Group type: COMPARATOR
Intervention: Auditory-only (AO) mode
Number of subjects: 23
Study 25222104 — intervention group
Group type: COMPARATOR
Intervention: 10 dB SL (re:SRT)
Number of subjects: 23
Study 22981031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin, vitamin E, and homocysteine lowering therapy
Number of subjects: 93
Study 22981031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 20522572 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-1 (cardiopulmonary exercise test 1)
Number of subjects: 0
Study 20522572 — intervention group
Group type: COMPARATOR
Intervention: CPX-0 (cardiopulmonary exercise test 0)
Number of subjects: 0
Study 20522572 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Vo2
Number of subjects: 0
Study 20522572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory efficiency
Number of subjects: 0
Study 20522572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory-derived anaerobic threshold
Number of subjects: 0
Study 17989119 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with one or fewer major breaks per session
Number of subjects: 98
Study 17989119 — intervention group
Group type: COMPARATOR
Intervention: Patients with more than one major break per session
Number of subjects: 98
Study 16045048 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with researchers
Number of subjects: 0
Study 11377644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg twice daily)
Number of subjects: 404
Study 11377644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 9647605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteinyl leukotriene receptor antagonist (zafirlukast)
Number of subjects: 0
Study 9647605 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-lipoxygenase inhibitor (zileuton)
Number of subjects: 0
Study 9647605 — intervention group
Group type: EXPERIMENTAL
Intervention: Antileukotriene agents (general)
Number of subjects: 0
Study 8049043 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure with a running 6‐0 fast‐absorbing catgut suture
Number of subjects: 20
Study 8049043 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular closure with a 5‐0 polypropylene suture (Prolene)
Number of subjects: 20
Study 8049043 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study 2542682 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone (0.8 mg i.v.)
Number of subjects: 17
Study 2542682 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 1146722 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocopherol-stripped safflower oil containing 88 g of polyunsaturated fatty acids and 2.3 mg of tocopherols.
Number of subjects: 35
Study 1146722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation, low vitamin E diet).
Number of subjects: 35
Study 30418340 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sinaki exercises
Number of subjects: 91
Study 30418340 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking workout
Number of subjects: 91
Study 30418340 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of modified Sinaki exercises and Nordic Walking
Number of subjects: 91
Study 30418340 — intervention group
Group type: COMPARATOR
Intervention: Control group (drugs only)
Number of subjects: 91
Study 28609475 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and coenzyme Q10 supplementation
Number of subjects: 215
Study 28609475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 26404895 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily exercise programme
Number of subjects: 469
Study 25514490 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 70
Study 25514490 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 0.2% epinephrine
Number of subjects: 70
Study 22310310 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase (NOS) inhibition via intra-arterial infusion of N(G)-monomethyl-L-arginine (L-NMMA)
Number of subjects: 6
Study 22310310 — intervention group
Group type: COMPARATOR
Intervention: Passive limb movement (control)
Number of subjects: 6
Study 20027346 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN inductor anaferon (pediatric formulation)
Number of subjects: 0
Study 17463304 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin per day
Number of subjects: 14
Study 17463304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15120769 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong opioids
Number of subjects: 100
Study 15120769 — intervention group
Group type: COMPARATOR
Intervention: WHO guidelines
Number of subjects: 100
Study 11458138 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent targeted intervention (MTI) to prevent delirium
Number of subjects: 852
Study 11458138 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital care
Number of subjects: 852
Study 9017526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate (MSR) 20-40 mg/day
Number of subjects: 8
Study 9017526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9017526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate (MSR)
Number of subjects: 8
Study 8506913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 2000 mg
Number of subjects: 10
Study 2951051 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg doxazosin
Number of subjects: 18
Study 2951051 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg doxazosin
Number of subjects: 18
Study 2951051 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg doxazosin
Number of subjects: 18
Study 2951051 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (2, 4, and 8 mg)
Number of subjects: 18
Study 2951051 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 18
Study 29463933 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe resistance training combined with traditional aerobic exercise
Number of subjects: 12
Study 29463933 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise only (Control)
Number of subjects: 12
Study 26414236 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 104
Study 26414236 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 104
Study 23994382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegasys (PegIFNα) weekly dosing of 360 μg
Number of subjects: 28
Study 23994382 — intervention group
Group type: EXPERIMENTAL
Intervention: Viread (tenofovir disoproxil fumarate, TDF) daily dose of 300 mg
Number of subjects: 28
Study 23994382 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Pegasys and Viread
Number of subjects: 28
Study 23994382 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 28
Study 22743137 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hCG administration (hCG 5000 IU, IM when leading follicle diameter 16.0-16.9 mm)
Number of subjects: 612
Study 22743137 — intervention group
Group type: COMPARATOR
Intervention: Late hCG administration (hCG 5000 IU, IM when leading follicle diameter 18.0-18.9 mm)
Number of subjects: 612
Study 20845002 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavocoxid (500 mg twice daily)
Number of subjects: 220
Study 20845002 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg twice daily)
Number of subjects: 220
Study 18450119 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 38
Study 18450119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 16630151 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA(2) peptide vaccine
Number of subjects: 12
Study 16630151 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated subjects)
Number of subjects: 12
Study 14714934 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-animated tutor (Baldi) for vocabulary and grammar learning
Number of subjects: 14
Study 14714934 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-animated tutor (Baldi)
Number of subjects: 14
Study 10618542 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV SF2 gp120/MF59 vaccine (50 microg)
Number of subjects: 52
Study 10618542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 8839901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole 1 mg twice daily
Number of subjects: 212
Study 8839901 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg daily
Number of subjects: 212
Study 8136396 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (10 to 20 micrograms/kg)
Number of subjects: 40
Study 8136396 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1 to 2 micrograms/kg)
Number of subjects: 40
Study 8136396 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil and Fentanyl
Number of subjects: 40
Study 3323603 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (40% of VO2 max)
Number of subjects: 20
Study 3323603 — intervention group
Group type: COMPARATOR
Intervention: Propranolol and metoprolol (beta adrenergic antagonists)
Number of subjects: 20
Study 31929405 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)
Number of subjects: 447
Study 31929405 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls with no severe outcomes)
Number of subjects: 447
Study 29866385 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioral treatment (BT) based on motivational interviewing and cognitive behavioral therapy
Number of subjects: 392